+

WO2000062813A3 - Cationic peg-lipids and methods of use - Google Patents

Cationic peg-lipids and methods of use Download PDF

Info

Publication number
WO2000062813A3
WO2000062813A3 PCT/CA2000/000451 CA0000451W WO0062813A3 WO 2000062813 A3 WO2000062813 A3 WO 2000062813A3 CA 0000451 W CA0000451 W CA 0000451W WO 0062813 A3 WO0062813 A3 WO 0062813A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipid
cationic
lipids
methods
cpls
Prior art date
Application number
PCT/CA2000/000451
Other languages
French (fr)
Other versions
WO2000062813A2 (en
Inventor
Pieter R Cullis
Tao Chen
David B Fenske
Lorne R Palmer
Kim Wong
Original Assignee
Univ British Columbia
Pieter R Cullis
Tao Chen
David B Fenske
Lorne R Palmer
Kim Wong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia, Pieter R Cullis, Tao Chen, David B Fenske, Lorne R Palmer, Kim Wong filed Critical Univ British Columbia
Priority to JP2000611949A priority Critical patent/JP5117648B2/en
Priority to EP00920309A priority patent/EP1173600A2/en
Priority to AU40962/00A priority patent/AU783647B2/en
Priority to CA002370690A priority patent/CA2370690A1/en
Publication of WO2000062813A2 publication Critical patent/WO2000062813A2/en
Priority to EP01927519A priority patent/EP1355670A2/en
Priority to AU2001254548A priority patent/AU2001254548B2/en
Priority to US09/839,707 priority patent/US7189705B2/en
Priority to AU5454801A priority patent/AU5454801A/en
Priority to CA002406654A priority patent/CA2406654A1/en
Priority to JP2001577996A priority patent/JP2004508012A/en
Priority to PCT/CA2001/000555 priority patent/WO2001080900A2/en
Publication of WO2000062813A3 publication Critical patent/WO2000062813A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides cationic-polymer-lipid conjugates (CPLs) such as distal cationic-poly(ethylene glycol)-lipid conjugates which can be incorporated into conventional and stealth liposomes or other lipid-based formulation for enhancing cellular uptake. The CPLs of the present invention comprise a lipid moiety; a hydrophilic polymer; and a polycationic moiety. Method of increasing intracellular delivery of nucleic acids are also provided.
PCT/CA2000/000451 1999-04-20 2000-04-20 Cationic peg-lipids and methods of use WO2000062813A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
JP2000611949A JP5117648B2 (en) 1999-04-20 2000-04-20 Cationic PEG lipids and methods of use.
EP00920309A EP1173600A2 (en) 1999-04-20 2000-04-20 Cationic peg-lipids and methods of use
AU40962/00A AU783647B2 (en) 1999-04-20 2000-04-20 Cationic peg-lipids and methods of use
CA002370690A CA2370690A1 (en) 1999-04-20 2000-04-20 Cationic peg-lipids and methods of use
PCT/CA2001/000555 WO2001080900A2 (en) 2000-04-20 2001-04-20 Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane
EP01927519A EP1355670A2 (en) 2000-04-20 2001-04-20 Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane destabilisers
AU2001254548A AU2001254548B2 (en) 2000-04-20 2001-04-20 Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane
US09/839,707 US7189705B2 (en) 2000-04-20 2001-04-20 Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
AU5454801A AU5454801A (en) 2000-04-20 2001-04-20 Methods of enhancing splp-mediated transfection using endosomal membrane destabilizers
CA002406654A CA2406654A1 (en) 2000-04-20 2001-04-20 Methods of enhancing splp-mediated transfection using endosomal membrane destabilizers
JP2001577996A JP2004508012A (en) 2000-04-20 2001-04-20 Methods for enhancing SPLP-mediated transfection using endosomal membrane destabilizing agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13015199P 1999-04-20 1999-04-20
US60/130,151 1999-04-20

Publications (2)

Publication Number Publication Date
WO2000062813A2 WO2000062813A2 (en) 2000-10-26
WO2000062813A3 true WO2000062813A3 (en) 2001-08-09

Family

ID=22443303

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/000451 WO2000062813A2 (en) 1999-04-20 2000-04-20 Cationic peg-lipids and methods of use

Country Status (5)

Country Link
EP (1) EP1173600A2 (en)
JP (2) JP5117648B2 (en)
AU (1) AU783647B2 (en)
CA (1) CA2370690A1 (en)
WO (1) WO2000062813A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4656675B2 (en) 1997-05-14 2011-03-23 ユニバーシティー オブ ブリティッシュ コロンビア High rate encapsulation of charged therapeutic agents in lipid vesicles
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
AU5454801A (en) * 2000-04-20 2001-11-07 Univ British Columbia Methods of enhancing splp-mediated transfection using endosomal membrane destabilizers
EP1328254B1 (en) * 2000-10-25 2007-02-21 The University Of British Columbia Lipid formulations for target delivery
US6610322B1 (en) * 2000-12-20 2003-08-26 Brian Charles Keller Self forming, thermodynamically stable liposomes and their applications
ES2354607T3 (en) 2002-06-28 2011-03-16 Protiva Biotherapeutics Inc. PROCEDURE AND APPLIANCE TO PRODUCE LIPOSOMES.
WO2004082626A2 (en) * 2003-03-18 2004-09-30 Ethicon, Inc. Aromatase inhibitor diagnosis and therapy
AU2004257373B2 (en) 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
CA2551022C (en) * 2003-09-15 2013-06-04 Protiva Biotherapeutics, Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
FR2870741B1 (en) 2004-05-25 2008-03-14 Coletica Sa HYDRATED LAMELLAR OR LIPOSOME PHASE CONTAINING A FATTY MONOAMINE OR A CATIONIC POLYMER PROMOTING INTERCELLULAR PENETRATION AND A COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING THE SAME.
ATE536418T1 (en) 2004-06-07 2011-12-15 Protiva Biotherapeutics Inc LIPID ENCAPSULATED INTERFERENCE RNA
WO2007028341A1 (en) * 2005-09-09 2007-03-15 Beijing Diacrid Medical Technology Co., Ltd. Nano anticancer micelles of vinca alkaloids entrapped in polyethylene glycolylated phospholipids
JP5336853B2 (en) 2005-11-02 2013-11-06 プロチバ バイオセラピューティクス インコーポレイティッド Modified siRNA molecules and methods of use thereof
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
CA2710713C (en) 2007-12-27 2017-09-19 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering rna
EP2281041B1 (en) 2008-04-15 2014-07-02 Protiva Biotherapeutics Inc. Silencing of csn5 gene expression using interfering rna
PT2279254T (en) 2008-04-15 2017-09-04 Protiva Biotherapeutics Inc Novel lipid formulations for nucleic acid delivery
AU2009236306B2 (en) 2008-04-17 2015-04-02 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
WO2011000107A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
US8716464B2 (en) 2009-07-20 2014-05-06 Thomas W. Geisbert Compositions and methods for silencing Ebola virus gene expression
CA2775092A1 (en) 2009-09-23 2011-03-31 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes expressed in cancer
PT2506857T (en) 2009-12-01 2018-05-14 Translate Bio Inc Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
WO2011141704A1 (en) 2010-05-12 2011-11-17 Protiva Biotherapeutics, Inc Novel cyclic cationic lipids and methods of use
EP2569276B1 (en) 2010-05-12 2021-02-24 Arbutus Biopharma Corporation Novel cationic lipids and methods of use thereof
CA2802994A1 (en) 2010-06-17 2011-12-22 The United States Of America As Represented By The Secretary, National I Nstitutes Of Health Compositions and methods for treating inflammatory conditions
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
WO2012170930A1 (en) 2011-06-08 2012-12-13 Shire Human Genetic Therapies, Inc Lipid nanoparticle compositions and methods for mrna delivery
US11073451B2 (en) 2011-12-19 2021-07-27 Kode Biotech Limited Biocompatible method of functionalising substrates with inert surfaces
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
EP2817287B1 (en) 2012-02-24 2018-10-03 Arbutus Biopharma Corporation Trialkyl cationic lipids and methods of use thereof
KR20200036033A (en) * 2012-03-16 2020-04-06 메르크 파텐트 게엠베하 Targeting aminoacid lipids
EP2859102A4 (en) 2012-06-08 2016-05-11 Shire Human Genetic Therapies Nuclease resistant polynucleotides and uses thereof
US10286064B2 (en) 2012-06-15 2019-05-14 Pds Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
WO2014047533A1 (en) 2012-09-21 2014-03-27 Frank Bedu-Addo Improved vaccine compositions and methods of use
EP3446712A1 (en) 2013-03-14 2019-02-27 Translate Bio Ma, Inc. Cftr mrna compositions and related methods and uses
JP6586075B2 (en) 2013-03-14 2019-10-02 トランスレイト バイオ， インコーポレイテッド Method for purifying messenger RNA
US20160151284A1 (en) 2013-07-23 2016-06-02 Protiva Biotherapeutics, Inc. Compositions and methods for delivering messenger rna
EA201992208A1 (en) 2013-10-22 2020-07-31 Транслейт Био, Инк. TREATMENT OF PHENYLKETONURIA USING mRNA
CA2928188A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Mrna therapy for argininosuccinate synthetase deficiency
SG11201608725YA (en) 2014-04-25 2016-11-29 Shire Human Genetic Therapies Methods for purification of messenger rna
US10415037B2 (en) 2014-10-02 2019-09-17 Arbutus Biopharma Corporation Compositions and methods for silencing hepatitis B virus gene expression
US20180245074A1 (en) 2015-06-04 2018-08-30 Protiva Biotherapeutics, Inc. Treating hepatitis b virus infection using crispr
US20180208932A1 (en) 2015-07-29 2018-07-26 Arbutus Biopharma Corporation Compositions and methods for silencing hepatitis b virus gene expression
BR112018003784A2 (en) 2015-08-24 2018-09-25 Halo-Bio Rnai Therapeutics, Inc. polynucleotide nanoparticles for the modulation of gene expression and its use
CA3005251A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
US11191849B2 (en) 2016-06-30 2021-12-07 Arbutus Biopharma Corporation Compositions and methods for delivering messenger RNA
MX2019010155A (en) 2017-02-27 2020-12-10 Translate Bio Inc Novel codon-optimized cftr mrna.
CA3063531A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
EP3841208A1 (en) 2018-08-24 2021-06-30 Translate Bio, Inc. Methods for purification of messenger rna
EP3883592A1 (en) 2018-11-21 2021-09-29 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr
GB201910299D0 (en) 2019-07-18 2019-09-04 Aouadi Myriam Medical uses, methods and uses
CA3162374A1 (en) * 2019-12-20 2021-06-24 So Jin Lee Kit for preparing nanoparticle composition for drug delivery, comprising polylactic acid salt
JP2023518944A (en) 2020-03-17 2023-05-09 ジェネヴァント サイエンシズ ゲーエムベーハー Cationic lipids for lipid nanoparticle delivery of therapeutic agents to hepatic stellate cells
JP2023553343A (en) 2020-11-25 2023-12-21 アカゲラ・メディスンズ，インコーポレイテッド Lipid nanoparticles and related methods of use for delivering nucleic acids
WO2023144798A1 (en) 2022-01-31 2023-08-03 Genevant Sciences Gmbh Ionizable cationic lipids for lipid nanoparticles
US12064479B2 (en) 2022-05-25 2024-08-20 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
WO2024214632A1 (en) * 2023-04-14 2024-10-17 国立大学法人 東京大学 Phosphonium group-containing cationic polymer, and polymer particles and pharmaceutical composition containing same
WO2025052278A1 (en) 2023-09-05 2025-03-13 Genevant Sciences Gmbh Pyrrolidine based cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016202A2 (en) * 1996-10-11 1998-04-23 Sequus Pharmaceuticals, Inc. Fusogenic liposome composition and method
WO1998046208A1 (en) * 1997-04-17 1998-10-22 The Regents Of The University Of Michigan Hair follicle dna delivery system
WO1998051285A2 (en) * 1997-05-15 1998-11-19 Genzyme Corporation Cationic amphiphile formulations
WO1999005303A1 (en) * 1997-07-24 1999-02-04 Inex Pharmaceuticals Corporation Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method
WO1999005094A1 (en) * 1997-07-23 1999-02-04 Ribozyme Pharmaceuticals, Incorporated Novel compositions for the delivery of negatively charged molecules
WO1999065461A2 (en) * 1998-06-19 1999-12-23 Genzyme Corporation Cationic amphiphile micellar complexes
WO2000043043A1 (en) * 1999-01-21 2000-07-27 Georgetown University Ligand-peg post-coating stabilized lipoplex and polyplex for targeted gene delivery

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69632401T2 (en) * 1995-06-07 2005-05-19 Imarx Pharmaceutical Corp., Tucson NEW TARGETED MEANS FOR DIAGNOSTIC AND THERAPEUTIC USE
EP0932390A1 (en) * 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
EP1046394A3 (en) * 1999-04-19 2001-10-10 ImaRx Pharmaceutical Corp. Novel compositions useful for delivering compounds into a cell
ATE374785T1 (en) * 2000-03-02 2007-10-15 Mitsubishi Pharma Corp GPIB BONDED CONSTRUCT AND USES THEREOF

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016202A2 (en) * 1996-10-11 1998-04-23 Sequus Pharmaceuticals, Inc. Fusogenic liposome composition and method
WO1998046208A1 (en) * 1997-04-17 1998-10-22 The Regents Of The University Of Michigan Hair follicle dna delivery system
WO1998051285A2 (en) * 1997-05-15 1998-11-19 Genzyme Corporation Cationic amphiphile formulations
WO1999005094A1 (en) * 1997-07-23 1999-02-04 Ribozyme Pharmaceuticals, Incorporated Novel compositions for the delivery of negatively charged molecules
WO1999005303A1 (en) * 1997-07-24 1999-02-04 Inex Pharmaceuticals Corporation Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method
WO1999065461A2 (en) * 1998-06-19 1999-12-23 Genzyme Corporation Cationic amphiphile micellar complexes
WO2000043043A1 (en) * 1999-01-21 2000-07-27 Georgetown University Ligand-peg post-coating stabilized lipoplex and polyplex for targeted gene delivery

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
ANWER K ET AL: "OPTIMIZATION OF CATIONIC LIPID/DNA COMPLEXES FOR SYSTEMIC GENE TRANSFER TO TUMOR LESIONS", JOURNAL OF DRUG TARGETING,HARWOOD ACADEMIC PUBLISHERS GMBH,DE, vol. 8, no. 2, 2000, pages 125 - 135, XP000951678, ISSN: 1061-186X *
ARUNA NATHAN ET AL: "COPOLYMERS OF LYSINE AND POLYETHYLENE GLYCOL: A NEW FAMILY OF FUNCTIONALIZED DRUG CARRIERS", BIOCONJUGATE CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY, WASHINGTON, vol. 4, no. 1, 1993, pages 54 - 62, XP000336592, ISSN: 1043-1802 *
BHATTACHARYA S V ET AL: "Synthesis of novel cationic lipids with oxyethylene spacers at the linkages between hydrocarbon chains and pseudoglyceryl backbone", TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 40, no. 46, 12 November 1999 (1999-11-12), pages 8167 - 8171, XP004180445, ISSN: 0040-4039 *
CHEN TAO ET AL: "Fluorescent-labeled poly(ethylene glycol) lipid conjugates with distal cationic headgroups.", BIOCONJUGATE CHEMISTRY, vol. 11, no. 3, May 2000 (2000-05-01), pages 433 - 437, XP002157295, ISSN: 1043-1802, Retrieved from the Internet <URL:http://pubs.acs.org/CHECKCCIP-979559877/isubscribe/journals/bcches/asap/pdf/bc990171x.pdf> [retrieved on 20000330] *
HASELGRUBLER T ET AL: "SYNTHESIS AND APPLICATIONS OF A NEW POLY(ETHYLENE GLYCOL) DERIVATIVE FOR THE CROSSLINKING OF AMINES WITH THIOLS", BIOCONJUGATE CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY, WASHINGTON, vol. 6, no. 3, 1 May 1995 (1995-05-01), pages 242 - 248, XP000505483, ISSN: 1043-1802 *
JAGUR-GRODZINSKI J: "Biomedical application of functional polymers", REACTIVE & FUNCTIONAL POLYMERS,NL,ELSEVIER SCIENCE PUBLISHERS BV, vol. 39, no. 2, 15 February 1999 (1999-02-15), pages 99 - 138, XP004160680, ISSN: 1381-5148 *
MACIAN M ET AL: "Preliminary studies of the toxic effects of non-ionic surfactants derived from lysine.", TOXICOLOGY, JAN 8 1996, VOL. 106, NO. 1-3, PAGE(S) 1-9, XP000978704 *
MORI A ET AL: "STABILIZATION AND REGULATED FUSION OF LIPOSOMES CONTAINING A CATIONIC LIPID USING AMPHIPATHIC POLYETHYLENEGLYCOL DERIVATIVES", JOURNAL OF LIPOSOME RESEARCH,US,MARCEL DEKKER, NEW YORK, vol. 8, no. 2, 1 May 1998 (1998-05-01), pages 195 - 211, XP000752693, ISSN: 0898-2104 *
See also references of EP1173600A2 *
TRUBETSKOY V S ET AL: "NEW APPROACHES IN THE CHEMICAL DESIGN OF GD-CONTAINING LIPOSOMES FOR USE IN MAGNETIC RESONANCE IMAGING OF LYMPH NODES", JOURNAL OF LIPOSOME RESEARCH,US,MARCEL DEKKER, NEW YORK, vol. 4, no. 2, 1994, pages 961 - 980, XP000619021, ISSN: 0898-2104 *
TRUBETSKOY V.S. ET AL: "New approaches in the chemical design of Gd-containing liposomes for use in magnetic resonance imaging of lymph nodes", JOURNAL OF LIPOSOME RESEARCH, 1994, VOL. 4, NO. 2, PAGE(S) 961-983, XP000978705 *
VESKA TONCHEVAL ET AL: "BLOCK COPOLYMERS WITH pH-DEPENDENT SECONDARYSTRUCTURE", JOURNAL OF CONTROLLED RELEASE, vol. 48, no. 2 - 3, October 1997 (1997-10-01), pages 301 - 302, XP002157296, ISSN: 0168-3659 *
WEISSIG V ET AL: "Long-circulating gadolinium-loaded liposomes: potential use for magnetic resonance imaging of the blood pool", COLLOIDS AND SURFACES B (BIOINTERFACES), OCT. 2000, ELSEVIER, NETHERLANDS, vol. 18, no. 3-4, pages 293 - 299, XP000971876, ISSN: 0927-7765 *
ZALIPSKY S ET AL: "LONG CIRCULATING, CATIONIC LIPOSOMES CONTAINING AMINO-PEG-PHOSPHATIDYLETHANOLAMINE", FEBS LETTERS,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM,NL, vol. 353, 1994, pages 71 - 74, XP002920144, ISSN: 0014-5793 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents

Also Published As

Publication number Publication date
WO2000062813A2 (en) 2000-10-26
AU4096200A (en) 2000-11-02
JP2012122075A (en) 2012-06-28
JP5117648B2 (en) 2013-01-16
JP2002542341A (en) 2002-12-10
AU783647B2 (en) 2005-11-17
EP1173600A2 (en) 2002-01-23
CA2370690A1 (en) 2000-10-26

Similar Documents

Publication Publication Date Title
WO2000062813A3 (en) Cationic peg-lipids and methods of use
WO2003103822A3 (en) Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)
WO2003068144A3 (en) Cytotoxic agents
FR2840532B1 (en) FURENT LIPID NANOCAPSULES, PROCESS FOR THEIR PREPARATION AND USE AS VECTOR OF ACTIVE (S) PRINCIPLES
WO2000061543A3 (en) Esters of l-carnitine or alkanoyl l-carnitines
WO2000065024A3 (en) Hyperbranched polymeric micelles for encapsulation and delivery of hydrophobic molecules
WO2001062299A3 (en) Water-soluble polymer conjugates of artelinic acid
WO2002034236A3 (en) Lipid formulations for target delivery
WO2003000233A3 (en) Delivery of small hydrophilic molecules packaged into lipid vesicles
CA2393638A1 (en) Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol)
AU1928501A (en) Formulations for pharmaceutical agents ionizable as free acids or free bases
CA2270396A1 (en) Cationic reagents for transfection
WO2002097116A3 (en) Delivery system for nucleic acids
WO2002038105A3 (en) Novel polyamine analog-amino acid conjugates useful as anticancer agents
CA2252055A1 (en) Fusogenic liposomes
CA2196780A1 (en) A liposomal delivery system comprising cationic lipopolyamines and neutral lipids for delivery of biologically active agents
MXPA02012068A (en) Liposomal benzoquinazoline thymidylate synthase inhibitor formulations.
WO2003045306A3 (en) Phenoxy amine compounds and compositions for delivering active agents
WO2002036161A3 (en) Novel targeted compositions for diagnostic and therapeutic use
AU2102101A (en) Use of cationic lipids for intracellular protein delivery
WO2007002886A3 (en) Compositions and methods for less immunogenic pr0tein-lip1d complexes
EP1068306A4 (en) Pentaerythritol lipid derivatives
EP2452684A3 (en) Micelles
WO2022226008A3 (en) Cationic lipids and compositions thereof
WO2004105697A3 (en) Novel lipids for transfection of nucleic acids

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2370690

Country of ref document: CA

Kind code of ref document: A

Country of ref document: CA

Ref document number: 2000 611949

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000920309

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000920309

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载